Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Concentration over time for each dose cohort of romidepsin (B).

    Blood, 2018, 131(4):397-407. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Impacts of chromopeptide A and FK228 on G2/M transition regulators. PC3 and LNCaP cells were treated with chromopeptide A or FK228 at indicated concentrations for 24 h, and cells lysates were immunoblotted with the indicated antibodies.

    Acta Pharmacol Sin, 2017, 38(4):551-560. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 MnHhR4VtdCCYaXHibYxqfHliQYPzZZk> MUiyMlUuOTVibl2= NYeyeZRLPzJiaB?= NIL1SVlqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MlW2NlU4QTB7MEe=
U2932  NU[3SmlFS2WubDDWbYFjcWyrdImgRZN{[Xl? Mn7LNk42NTF3IH7N MVG3NkBp M1HFU4lv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MUOyOVc6ODlyNx?=
OCI-LY7 MXzD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NIH5RpUzNjVvMUWgcm0> MY[3NkBp M17pTYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NFXicJYzPTd7MEmwOy=>
Farage NYXvV2FnS2WubDDWbYFjcWyrdImgRZN{[Xl? NESxboozNjVvMUWgcm0> NXfmR3k4PzJiaB?= M3WxNolv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M3;mV|I2PzlyOUC3
LY7/EBV NFTCempE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUSyMlUuOTVibl2= MoCwO|IhcA>? M4TDeYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? MYqyOVc6ODlyNx?=
U2932/EBV M123UGNmdGxiVnnhZoltcXS7IFHzd4F6 MlvpNk42NTF3IH7N NWDHOYp5PzJiaB?= NVTY[mxwcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NFjxUYczPTd7MEmwOy=>
HCT116 M1fzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLZ[45yPS13MECwJI5O NXHEdIZCOjRiaB?= M1vjWWROW09? MVHpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= NXjveXZmOjV2OUK1NVU>
ACH-2 NF7uW29HfW6ldHnvckBCe3OjeR?= NILP[IIyNTlibl2= M4fnelI1KGh? MVnpcoR2[2W|IFjJWk0yKEWwdjDlfJBz\XO|aX;u M4rzVlI2OTR7NE[3
MCF-10A M3iwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjwT|lKSzVyPUCuNVfDuTBwMEGgcm0> NEm1PI8zPDl3NEi1Oi=>
MCF-7 Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET6NVRKSzVyPUGuNVDDuTBwMkCgcm0> NFy1cI4zPDl3NEi1Oi=>
SK-BR-3 MlPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fMRmlEPTB;MT6wNOKyOC5|NTDuUS=> NWXDVFFwOjR7NUS4OVY>
MDA-MB-231 M1PmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTBwNklCtVAvOTRibl2= MViyOFk2PDh3Nh?=
PC3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrWbFBKSzVyPUGuOlXDuTBwM{Wgcm0> MUmyOFk2PDh3Nh?=
HCT116 NIW4[5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGwTWM2OD1zLkCwxtExNjByIH7N MYiyOFk2PDh3Nh?=
HCT116-p21-/- MmqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TKfGlEPTB;MT6yOuKyOC5|NzDuUS=> M3v5[FI1QTV2OEW2
S1 NIGySmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\pTWM2OD15Lk[3xtExNjJ7IH7N NVriU|h1OjR7NUS4OVY>
SW620 M2\Xbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlqwTWM2OD1yLkmzxtExNjJ7IH7N NY\JWoFNOjR7NUS4OVY>
LOX-IMVI NXnvZ3JLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwOEhCtVAvODNibl2= M2XFeFI1QTV2OEW2
UACC-62 MkfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwNUdCtVAvOTZibl2= MmTJNlQ6PTR6NU[=
MDA-MB-435 Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTBwOUFCtVAvODZibl2= NX\IcGFDOjR7NUS4OVY>
SF-295 NWDRUG8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXSZmtKSzVyPUCuPFjDuTBwMUWgcm0> MUKyOFk2PDh3Nh?=
A549 NG\aWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;GTWM2OD1zLkK2xtExNjJ2IH7N M{S5RVI1QTV2OEW2
H460 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTJwNUlCtVAvQDBibl2= MU[yOFk2PDh3Nh?=
EKVX NGnHdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\FUYJKSzVyPUGuN|PDuTBwM{Sgcm0> M{TXSFI1QTV2OEW2
H146 NYLod2F[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzYb4VKSzVyPUCuNlLDuTBwMEegcm0> NUTBcJZrOjR7NUS4OVY>
H526 M1vJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHZW4RMUUN3ME2wMlE2yrFyLkCzJI5O NWXFeWluOjR7NUS4OVY>
HuT-78 NGn1SZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LGVmlEPTB;MT63N:KyOC52NDDuUS=> NX2z[2Z{OjR7NUS4OVY>
HA MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInmVYMxNjZ{NT2xNI5O MkTnOFghcA>? NFm3TINqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? MWWyOFc4OTVzMB?=
MS-275 NWHwZ|doT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXqwMlYzPS1zMH7N MUK0PEBp NWrvSWZNcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MXeyOFc4OTVzMB?=
CD4 T M17xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXG0PEBp MWrFR|UxRTRwNdMxNU4xKG6P MkfONlQ4OjJ2NUS=
CD4 T M4CyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\kXos1QCCq M1TYeWNEPTB;MUC3xtEyOjZibl2= MX6yOFczOjR3NB?=
CD4+ T MofnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTFR|UxRTNibl2= M2HZPFI1PDl3MUC1
A549 NVv6SXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zRR|Ex6oDVMUCwxsBvVQ>? NFHNWY0zPC9|Nj:0PEBp NHnhXIpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= M2TBN|I1PDh3N{m5
JJN3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{[wUFI1NzR6IHi= NYm1Xm0yTUN3MEyx5qCKdk19IES45qCKcA>? MUOyOFA{ODF3MB?=
OPM-2 NXv1Znl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYKyOE81QCCq MXPFR|Uxez1z4pEJcm08KDR64pEJbC=> M13adVI1ODNyMUWw
RPMI-8226 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[0cIxzOjRxNEigbC=> NV[1dWVQTUN3MIO9NU456oDLbl27JFQ56oDLaB?= MVSyOFA{ODF3MB?=
U266 MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:yOE81QCCq MmDtSWM2OHN;MUFihKlvVTtiNElihKlp M36xNVI1ODNyMUWw
CA46 NH3OT|RCeG:ydH;zbZMhSXO|YYm= MkPDOkBp MlLIbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MmO4NlM6PjZzNkS=
DG75 MlHQRZBweHSxc3nzJGF{e2G7 MYe2JIg> M2Dafolv\HWlZYOgco8h[XCxcITvd4l{ MofmNlM6PjZzNkS=
Ramos NV:0OIxrSXCxcITvd4l{KEG|c3H5 Ml7vOkBp NXf4N3BmcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NV\aPHA5OjN7Nk[xOlQ>
ST486 MVvBdI9xfG:|aYOgRZN{[Xl? NHHEUWY3KGh? MV;pcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO= MmfmNlM6PjZzNkS=
HuT78 NGfJS3NCeG:ydH;zbZMhSXO|YYm= NHL3S48yNzFyL{GwNEBvVQ>? M4Ps[FQ5KGh? NVu2ZVNXcW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=> MojqNlM2OzJ5M{K=
DpVp35 NHO4OmRCeG:ydH;zbZMhSXO|YYm= NHrvUncyNzFyL{GwNEBvVQ>? M37CR|Q5KGh? Ml7HbY5lfWOnczDicJVvfCCjcH;weI9{cXN? Mn7kNlM2OzJ5M{K=
DpVp50 MXzBdI9xfG:|aYOgRZN{[Xl? MXmxM|ExNzFyMDDuUS=> NWPzSmZ4PDhiaB?= NXLUUGNscW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NGHEVFIzOzV|MkezNi=>
DpP75  NXLUfJVPSXCxcITvd4l{KEG|c3H5 MV[xM|ExNzFyMDDuUS=> NXewcG1IPDhiaB?= MY\pcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MXqyN|U{Ojd|Mh?=
SKOV-3 NEj2bVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXvO5oyOeLCk{Kwcm0> M1;4OFczKGh? MU\EUXNQ MofpdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MYiyN|AyODN2OB?=
Brca1 WT M3XQeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXaO44y6oDVMkDuUS=> M3\1fFczKGh? MVrEUXNQ NXrUfotUemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NHvKXmozOzBzMEO0PC=>
Brca1 Null MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPRNGlGOeLCk{Kwcm0> MUW3NkBp MX3EUXNQ M{\EVZJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv M{XjbVI{ODFyM{S4
OVCAR-8  MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\jd|HjiJN{MH7N MoCwO|IhcA>? NF24NFdFVVOR M3jXe5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MYSyN|AyODN2OB?=
NCI/ADR-RES MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlK1NgKBmzJybl2= NU\zblZxPzJiaB?= MWLEUXNQ NF;teWNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? M2O1S|I{ODFyM{S4
HCT116 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[1JI5ONTVyIN88US=> NX;1NnhGOjRiaB?= MW\EUXNQ MnnwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NIq2XmczOjl{NEm1PC=>
RKO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4q3PFUhdk1vNUCg{txO M4LucVI1KGh? M1rTd2ROW09? MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MUmyNlkzPDl3OB?=
CO115 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[1JI5ONTVyIN88US=> MljFNlQhcA>? MnTMSG1UVw>? MXHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NGnyVlQzOjl{NEm1PC=>
HFS M3X1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTDOUBvVQ>? M3izelI1NzR6L{eyJIg> MlzGbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> NVPPZ|NKOjJzME[yPFI>
LNCaP M33u[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV20VJE5PSCwTR?= NGGzNYozPC92OD:3NkBp M3G3O4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> MkPMNlIyODZ{OEK=
A549 MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\zOUBvVQ>? MXyyOE81QC95MjDo NWrXelBncW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? NX25PHJxOjJzME[yPFI>
697  NHjuVHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi3TWM2OOLCiU5ihKkzNjYEoH7N M1zqblIyPTN6MkG2
697-R M2HINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|Ux6oDLPfMAjVgvPsLibl5CpC=> M2LqSFIyPTN6MkG2
HUT78 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFvRNFJKSzVyPUGgcm0> M2PKcFIyOTl6NUS1
THJ-16T M1vMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULpOHhNOSCwTR?= NV;vToJbOjRiaB?= M1PXXIlvcGmkaYTzJINmdGxiZ4Lve5Rp NFTURW0zODhzMEW2PC=>
HCT116 NX3aUoNYTnWwY4Tpc44hSXO|YYm= M3jRPFIxKG6P MonYPEBp NH;DRnZud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= MYKyNFc{QTR3NB?=
B104  MXXGeY5kfGmxbjDBd5NigQ>? NVLt[|lqOiCwTR?= Mmj5NlQwPDhxN{KgbC=> NV7zO21XcW6lcnXhd4V{KHSqZTDzeZJn[WOnIHX4dJJme3Orb36gc4YhS0R{MNMg NInjNoQzODZ6NkWwOS=>
HL-60  MoC0R5l1d3SxeHnjbZR6KEG|c3H5 NUHCRlFEOS13MECgcm0> M3v5WVI1KGh? Ml7obY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MV6yNFYzPDF4Mx?=
HP100 MXLDfZRwfG:6aXPpeJkhSXO|YYm= MUCxMVUxOCCwTR?= NHns[pMzPCCq NHrabWJqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi M3vYZ|IxPjJ2MU[z
HL-60  Mn6zSpVv[3Srb36gRZN{[Xl? M331NlExKG6P M{j2VVQwPi9zNjDo M1zjdolv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= Mnu2NlA3OjRzNkO=
HP100 MlnlSpVv[3Srb36gRZN{[Xl? MkjhNVAhdk1? NWX3RZdSPC94L{G2JIg> MmnybY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq NHLtbVMzODZ{NEG2Ny=>
HL-60  MWLGeY5kfGmxbjDBd5NigQ>? NV60fGc4OTBvNUCwJI5O M{\yV|QhcA>? M3;oRoRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NVvacYFROjB4MkSxOlM>
HP100 MkjUSpVv[3Srb36gRZN{[Xl? M1jJZVExNTVyMDDuUS=> NWT3d41oPCCq M4TRR4Rm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= MmDGNlA3OjRzNkO=
11z M4XRc2tqdmG|ZTDBd5NigQ>? NYLac3ROOy1zMECgcm0> M4S2PZJm\HWlZYOgTGRCSyCnbor5cYF1cWNiYXP0bZZqfHliKFnDOVDDqD1iNj61JOKyKDBwNjDucY9tN0xr NHr0eIIzODZyNUG0OC=>
SKOV-3 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[0b|QwQC9zNjDuUS=> MX:0PEBp Mo[2bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MWiyNFQxPDV4NB?=
OVCAR-3 M4H4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\PNlQwQC9zNjDuUS=> NHL3NlI1QCCq M3zyd4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MkDQNlA1ODR3NkS=
HBL-2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKyMVExKG6P MmLLNlQhcA>? NVrEfYtsUUN3ME20MlMhdk1? MX6yNFA3QDB6MB?=
Jeko-1 MnrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXJRVAzNTVyIH7N MWSyOEBp M2jOXWlEPTB;MUGgcm0> M{PyfVIxODZ6MEiw
Granta-519 NXfYT21MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2GzN|UuPDBibl2= M1PUSlI1KGh? NIe3dJdKSzVyPUW4MlUhdk1? NWewfGJqOjByNkiwPFA>
L1236 MYrDfZRwfG:6aXPpeJkhSXO|YYm= NFXVW3YyKG6PLUGwNEDPxE1? MorzOFghcA>? Mn65SWM2OD1yLkC3JO69VQ>? NFjmfI4yQTJ|M{S3NC=>
L428 NX75SoJyS3m2b4TvfIlkcXS7IFHzd4F6 NEXFOZUyKG6PLUGwNEDPxE1? NELjOXA1QCCq MVnFR|UxRTBwNEOg{txO NVS4[FRwOTl{M{O0O|A>
KM-H2 MU\DfZRwfG:6aXPpeJkhSXO|YYm= NUPWWnNTOSCwTT2xNFAh|ryP MWO0PEBp M4H4eGVEPTB;MD61PEDPxE1? NYHJNJl2OTl{M{O0O|A>
L540Cy NFv2TnVEgXSxdH;4bYNqfHliQYPzZZk> M2faZVEhdk1vMUCwJO69VQ>? NHjPUmE1QCCq NXfxb4J3TUN3ME2wMlE3KM7:TR?= MXuxPVI{OzR5MB?=
G401 NEjPN|VHfW6ldHnvckBCe3OjeR?= M3f6blExKG6P M37xZ|I1NzR6L{eyJIg> NX7KcVJWTE2VTx?= M3fpcIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NGG2O4gyQTJ{MUW4Oi=>
STM91-01 MkH0SpVv[3Srb36gRZN{[Xl? MnrrNVAhdk1? MnzsNlQwPDhxN{KgbC=> NVjPNGlbTE2VTx?= MmrGbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MnT5NVkzOjF3OE[=
SJSC  MmnYSpVv[3Srb36gRZN{[Xl? Mn7nNVAhdk1? Ml\iNlQwPDhxN{KgbC=> NFW2fpBFVVOR NEWz[nVqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MkKxNVkzOjF3OE[=
BT16  NYLETYVRTnWwY4Tpc44hSXO|YYm= NFf5e4gyOCCwTR?= NUXMcnRyOjRxNEivO|IhcA>? NFrVd5lFVVOR MmXWbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u MXKxPVIzOTV6Nh?=
NCI-H1299 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfVemtkUUN3ME20MlbDuTBwMjDu[{9udA>? M{fGZVE6OTd7OEmw
NCI-2882 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS5[npzUUN3ME2xMlbDuTBwMESgcocwdWx? NYDPcYtpOTlzN{m4PVA>
HCC95 NWLk[GlKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUKy[4x5UUN3ME2yMlXDuTBwMEWgcocwdWx? NVfINYxHOTlzN{m4PVA>
NCI-H23 NFPOXopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;tZYZKSzVyPUKuPeKyOC5{IH7nM41t NHjvW|YyQTF5OUi5NC=>
NCI-H157 Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUGzdFZSUUN3ME2xMlbDuTBwMEKgcocwdWx? MWqxPVE4QTh7MB?=
NCI-H460 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnWdG1yUUN3ME2yMlHDuTBwMEegcocwdWx? NWPSWVF7OTlzN{m4PVA>
NCI-H1975 NH3QdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\Oe2VKSzVyPUGuN:KyOC5yNDDu[{9udA>? NWnvd4dsOTlzN{m4PVA>
NCI-H820 NHHJc2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPsW4VKSzVyPUKuOOKyOC5zIH7nM41t M3rtVVE6OTd7OEmw
NCI-H1650 NV3EXGpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzkTWM2OD12LkpCtVAvOyCwZz;tcC=> M37sOFE6OTd7OEmw
DTC1 M33LSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7MS|FwUUN3ME2wMlUyKG6P M1X5[FE5PTZ4MkS2
KAO NYT0bZE5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPWVlNKSzVyPUCuPVEhdk1? NYDqSGc3OTh3Nk[yOFY>
SU-CCS-1 M4DVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrLe5pKSzVyPUCuPFkhdk1? NWHhNGhPOTh3Nk[yOFY>
SYO-1 NVS2OZltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3hTWM2OD1yLk[3JI5O NF3HZYUyQDV4NkK0Oi=>
FUJI MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LLTmlEPTB;MT6zNUBvVQ>? M{LZNFE5PTZ4MkS2
SKNMC MljHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTSTWM2OD1zLkG3JI5O NX;hOlhpOTh3Nk[yOFY>
402-91 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PUU2lEPTB;MT6yOkBvVQ>? M2\mXFE5PTZ4MkS2
1765-92 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TYT2lEPTB;MT63O{BvVQ>? NHr4RWUyQDV4NkK0Oi=>
JN-DSRCT-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXsTWM2OD1zLkK1JI5O MlTDNVg2PjZ{NE[=
NMS-2PC NYjIcIZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzSTFNDUUN3ME2wMlgyKG6P MVKxPFU3PjJ2Nh?=
HL60 MmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTFwOE[gcm0> MYSxPFU3PjJ2Nh?=
A549 M1O5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTCWHVmUUN3ME2zMlI1KG6P MnnmNVg2PjZ{NE[=
SW480 M4jsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW0TWM2OD1{Lk[5JI5O M{S0cFE5PTZ4MkS2
MCF7 NHfy[GRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoG2TWM2OD1|LkW1JI5O NEflXYwyQDV4NkK0Oi=>
PC-3 NHnMfG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHyXoRLUUN3ME2yMlUyKG6P M{DOdVE5PTZ4MkS2
MMRU M1;nZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DaNGlEPTB;Mj61O{BvVQ>? NYnybIk{OTh3Nk[yOFY>
Hs68 NVSwe|kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLNTWM2OD1-MUCgcm0> NECzXFMyQDV4NkK0Oi=>
hMSC-001F MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIfVUIZKSzVyPU6xNEBvVQ>? MnHwNVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03703375 Not yet recruiting Lymphoma T-Cell Celgene October 15 2018 Phase 3
NCT03547700 Recruiting Lymphoma T-Cell Peripheral Ryan Wilcox|University of Michigan Cancer Center|Takeda|Big Ten Cancer Research Consortium September 26 2018 Phase 1|Phase 2
NCT03355768 Not yet recruiting Lymphoma T-Cell Peripheral Jennifer Amengual|Columbia University September 2018 Phase 3
NCT03593018 Not yet recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene September 2018 Phase 3
NCT03161223 Recruiting Lymphoma T-Cell Columbia University|University of Bologna|Samsung Medical Center|Celgene June 1 2018 Phase 1|Phase 2
NCT03432741 Recruiting Breast Adenocarcinoma|Recurrent Breast Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Mycosis Fungoides|Recurrent Non-Hodgkin Lymphoma|Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Hodgkin Lymphoma|Refractory Mycosis Fungoides|Refractory Nodal Marginal Zone Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma|Stage IV Breast Cancer AJCC v6 and v7 Mayo Clinic|National Cancer Institute (NCI) March 27 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products4

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID